RE:RE:RE:Bristol Meyers Squibb CEO to step down April 27, 2023 - Striking deals remains Bristol’s “top priority,” CFO David Elkins said during [Thursday's investor's call]. BMS will continue to look for deals in fields where the company has deep R&D and commercial expertise, regardless of the stage of the program, he said.
Bristol’s core focus areas are solid tumors, hematology, immunology and cardiovascular disease.
https://www.fiercepharma.com/pharma/bristol-myers-still-looks-late-stage-ma-deals-despite-multiple-new-launches-ceo